«Many investors expected a more lengthy FDA review process
of the JCAR015 trial (and
potentially other CAR - T programs) and feared that a
higher -
degree regulatory scrutiny could increase the development
risk of CAR T cell,» Leerink Research said in a note co-authored by analysts Michael Schmidt, Ph.D., Jonathan Chang, Ph.D., and Varun Kumar, Ph.D. «While it may take several weeks to reopen all clinical sites
of the ROCKET trial, we believe the trial shouldn't be delayed by more than ~ 3 months.»
During extreme heat events, nighttime temperatures in the region's big cities are generally several
degrees higher28 than surrounding regions, leading to increased heat - related death among those less able to recover from the heat
of the day.36 Since the hottest days in the Northeast are often associated with
high concentrations
of ground - level ozone and other pollutants, 37 the combination
of heat stress and poor air quality can pose a major health
risk to vulnerable groups: young children, the elderly, and those with pre-existing health conditions including asthma.29 Vulnerability is further increased as key infrastructure, including electricity for
potentially life - saving air conditioning, is more likely to fail precisely when it is most needed — when demand exceeds available supply.